Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1986 1
1987 1
1988 5
1989 1
1991 1
1992 3
1994 1
1995 5
1996 4
1997 10
1998 4
1999 4
2000 4
2001 1
2002 1
2003 1
2004 1
2005 4
2006 3
2007 6
2008 9
2009 12
2010 12
2011 15
2012 10
2013 8
2014 10
2015 14
2016 18
2017 4
2018 2
2019 2
2020 5
2021 7
2022 3
2023 4
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Bielack SS, et al. Among authors: hoogerbrugge pm. J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. J Clin Oncol. 2015. PMID: 26033801 Free PMC article. Clinical Trial.
Gene therapy.
Kay MA, Liu D, Hoogerbrugge PM. Kay MA, et al. Among authors: hoogerbrugge pm. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12744-6. doi: 10.1073/pnas.94.24.12744. Proc Natl Acad Sci U S A. 1997. PMID: 9398067 Free PMC article. Review.
Immunocombination therapy for high-risk neuroblastoma.
Kroesen M, Lindau D, Hoogerbrugge P, Adema GJ. Kroesen M, et al. Among authors: hoogerbrugge p. Immunotherapy. 2012 Feb;4(2):163-74. doi: 10.2217/imt.11.169. Immunotherapy. 2012. PMID: 22394368 Review.
IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia.
Vervoort BMT, Butler M, Grünewald KJT, Schenau DSVI, Tee TM, Lucas L, Huitema ADR, Boer JM, Bornhauser BC, Bourquin JP, Hoogerbrugge PM, Van der Velden VHJ, Kuiper RP, Van der Meer LT, Van Leeuwen FN. Vervoort BMT, et al. Among authors: hoogerbrugge pm. Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.284357. Online ahead of print. Haematologica. 2024. PMID: 38841778 Free article.
HDAC inhibitors and immunotherapy; a double edged sword?
Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. Kroesen M, et al. Among authors: hoogerbrugge pm. Oncotarget. 2014 Aug 30;5(16):6558-72. doi: 10.18632/oncotarget.2289. Oncotarget. 2014. PMID: 25115382 Free PMC article. Review.
Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.
Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, van der Velden V, Beverloo HB, Bierings M, Dors N, de Haas V, Hoogerbrugge P, Van der Sluis I, Tissing W, Veening M, Boer J, Den Boer M. Pieters R, et al. Among authors: hoogerbrugge p. J Clin Oncol. 2023 Sep 1;41(25):4130-4142. doi: 10.1200/JCO.22.02705. Epub 2023 Jul 17. J Clin Oncol. 2023. PMID: 37459571
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM. Ceolin V, et al. Among authors: hoogerbrugge p. Leukemia. 2023 Jan;37(1):53-60. doi: 10.1038/s41375-022-01740-9. Epub 2022 Oct 30. Leukemia. 2023. PMID: 36310183
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
van der Sluis IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, Bierings M, van den Bos C, de Haas V, Hoogerbrugge PM, Tissing WJE, Veening MA, Pieters R. van der Sluis IM, et al. Among authors: hoogerbrugge pm. J Clin Oncol. 2024 May 10;42(14):1676-1686. doi: 10.1200/JCO.23.01797. Epub 2024 Feb 2. J Clin Oncol. 2024. PMID: 38306592 Free PMC article. Clinical Trial.
Retroviral stem cell gene therapy.
Havenga M, Hoogerbrugge P, Valerio D, van Es HH. Havenga M, et al. Among authors: hoogerbrugge p. Stem Cells. 1997;15(3):162-79. doi: 10.1002/stem.150162. Stem Cells. 1997. PMID: 9170208 Review.
168 results